| Document |
Document Title |
|
WO/2023/284848A1 |
The present invention relates to the field of biotechnology, and specifically discloses fructooligosaccharide having high kestose content and an application thereof. In the fructooligosaccharide having high kestose content in the present...
|
|
WO/2022/263718A1 |
The present invention relates to a method for producing cationic saccharide comprising providing a mixture comprising betaine aldehyde and a saccharide;allowing the betaine aldehyde to react with the saccharide; and obtaining cationic sa...
|
|
WO/2022/266359A1 |
This disclosure relates to a product, a beverage product, and an infusion formulation that each include at least two rare sugars, for example allulose and tagatose. The combination of allulose and tagatose synergistically sweeten the pro...
|
|
WO/2022/256467A1 |
The present invention is related to pharmaceutical formulations comprising a synthetic deoxypentitol and methods of use thereof in treating cancer.
|
|
WO/2022/243313A1 |
This invention relates to a method of producing mixtures of various human milk oligosaccharides (HMOs) with unique HMO blend profiles, consisting predominantly of LNFP-I and LNT and of other HMOs in less significant amounts. The less abu...
|
|
WO/2022/243307A1 |
This invention relates to multiple genetic engineering approaches applied to enhance the formation of the human milk oligosaccharide (HMO) lacto-N-triose II (LNT-II). Several aspects towards the construction of a beneficial LNT-II cell f...
|
|
WO/2022/239027A1 |
The present disclosure relates to a system and method for purifying D-allulose and/or fructose from a binary mixture.
|
|
WO/2022/239026A1 |
The present disclosure relates to a system and a method for crystallizing allulose from an allulose solution.
|
|
WO/2022/239028A1 |
The present disclosure relates to a system and method for separating and/or purifying D-allulose from a ternary mixture.
|
|
WO/2022/229316A1 |
Infant formulae with a very low level of arsenic are obtained by selecting the components of the infant formula very carefully. For manufacturing infant formulae that comprise less than 95 parts per billion (ppb) of arsenic, it is prefer...
|
|
WO/2022/221970A1 |
The present disclosure provides methods and enzymes for converting amino sugar to fructose and ammonia, wherein the enzyme is glucosamine-6-phosphate deaminase (GPDA enzyme), and the amino sugar is an amino monosaccharide, preferably a g...
|
|
WO/2022/223652A1 |
The present invention relates to a new method for drying human milk oligosaccharides (HMOs). This method allows to obtain HMOs with a very low water activity.
|
|
WO/2022/219094A1 |
The present invention relates to a process for producing isomalt compositions enriched in 1-O-α-D-glucopyranosyl-D-mannitol (hereinafter 1,1-GPM) and/or in 6-O-α-D-glucopyranosyl-D-sorbitol (hereinafter 1,6-GPS) from isomalt-containing...
|
|
WO/2022/191312A1 |
[Abstract] [Problem] To provide a method for producing a dealkoxyphenylation product with high yield from a substrate, e.g., a sugar, which is bonded to an alkoxyphenyl group through an oxygen atom. [Solution] A substrate that is bonded ...
|
|
WO/2022/187344A1 |
This invention relates to the isolation and purification of nutritional supplements and prebiotics, such as xylo-oligosaccharides, and specifically the removal of color bodies, said xylo-oligosaccharides sourced from from ligno-cellulosi...
|
|
WO/2022/164316A1 |
The invention relates to a saponin conjugate comprising a saponin derivative based on a saponin comprising a triterpene aglycone and at least one of a first saccharide chain and a second saccharide chain linked to the aglycone core struc...
|
|
WO/2022/157280A1 |
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of sialylated human milk oligosaccharides (H...
|
|
WO/2022/138748A1 |
The present invention provides a labeling method that comprises a step for labeling a substrate, which has a carbon-hydrogen bond, with an oxygen isotope with use of a catalyst and an oxidant that is produced from a hypervalent iodine co...
|
|
WO/2022/130322A1 |
The present invention concerns a method for separating different oligosaccharides having at least one carboxylic acid group, also referred to as charged oligosaccharides. The method allows for the high throughput separation of oligosacch...
|
|
WO/2022/127997A1 |
The invention relates to the use of ß-galactooligosaccharides of the general formula (ß gal (1→a))p - ß gal (1→b) glu, where p=0 to 6, a=2,3,4 or 6, and b=4 or 6, for producing a cosmetic and/or pharmacologically active compositio...
|
|
WO/2022/117739A1 |
The present invention relates to storage-stable formulations of oligosaccharide preparations suitable for use in nutritional compositions such as animal feed.
|
|
WO/2022/117074A1 |
The present application relates to a method for preparing crystalline D-psicose. In the present application, crystalline D-psicose is prepared by means of combining an evaporative crystallization method and a cooling crystallization meth...
|
|
WO/2022/115353A1 |
Described are methods of reducing exercise-induced injury and/or enhancing muscle recovery after exercise in a subject by administering an effective amount of 2'-fucosyllactose (2'FL). Said effective amount will increases the subject's e...
|
|
WO/2022/107013A1 |
The present invention relates to a process for the synthesis of Fondaparinux pentasaccharide and its intermediates. Specifically, the present invention relates to a novel catalytic process for the synthesis of Fondaparinux pentasaccharid...
|
|
WO/2022/067131A9 |
Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for decreasing inflammation for the treatm...
|
|
WO/2022/072323A1 |
This specification relates to a process for preparing a purified human milk oligosaccharide ("HMO") from an HMO-containing solution (e.g., a fermentation broth) by a process comprising mixed bed ion exchange, and a product of such a proc...
|
|
WO/2022/072333A1 |
This specification relates to a process for preparing a purified human milk oligosaccharide ("HMO") from an HMO-containing solution (e.g., a fermentation broth) by a process comprising anion ion exchange, cation ion exchange, and mixed b...
|
|
WO/2022/065744A1 |
Provided according to one embodiment of the present invention are nanoparticles, each nanoparticle comprising a core structure, and a shell structure covering the core structure and separated therefrom by a nanogap, wherein on the surfac...
|
|
WO/2022/067321A1 |
An improved process for extracting biological material from sugar-bearing plant material. In particular, the sugar-bearing plant material is treated with an extractant solution comprising water and a functionalized amphiphilic polymer, w...
|
|
WO/2020/249584A9 |
Disclosed is a process for the purification of LNnT (lacto-N-neotetraose) from a fermentation broth, the process comprises subjecting a fermentation broth to a first step of membrane filtration, thereby providing a filtrated solution, su...
|
|
WO/2022/055352A1 |
The invention relates to a saponin derivative based on a saponin comprising a triterpene aglycone and at least one of a first saccharide chain and a second saccharide chain linked to the aglycone core structure, wherein the saponin deriv...
|
|
WO/2022/056428A1 |
5'-O-(Acetoacetyl)-2',3'-di-O-acetyluridine is useful in the treatment or prevention of disorders characterized by cerebral metabolic energy failure or diminished mitochondrial energy reserve capacity.
|
|
WO/2022/049307A1 |
The invention relates to a process for the preparation of a product allulose composition comprising the steps of (a) providing a liquid allulose composition comprising allulose dissolved in water; (b) optionally, heating the liquid allul...
|
|
WO/2022/038198A1 |
Monosaccharide compounds, in particular deoxy-pentose compounds and preferably 5-azido-5-deoxy-D-arabinofuranose, for use in for use in labelling and/or concentrating and/or targeting and/or diagnosis of cell secretions from eukaryotic c...
|
|
WO/2022/029010A1 |
Food product, comprising 5.00 to 99.99% by weight of a crystalline beet-sugar sucrose preparation enriched in low-melting sucrose phase (LSP) and 0.01 to 95.00% by weight of at least one food component, and method for its production.
|
|
WO/2022/008693A1 |
The present invention relates to a process which makes it possible to obtain a plurality of organic compounds that can be used as chemical intermediates through the use of waste cellulosic biomass as a raw material. Through this process ...
|
|
WO/2021/260562A1 |
The invention relates to a method for synthesising macromolecules made up of units U that are mostly monosaccharides or monosaccharide derivatives, by successive elongation of a first unit U1 attached by a covalent bond to an anchor mole...
|
|
WO/2021/250191A1 |
The present invention relates to a method for improved demineralization of fermentation broths, including the steps of providing a solution comprising one or more oligosaccharides, carrying out a first membrane filtration and preferably ...
|
|
WO/2021/239813A1 |
The invention relates to a process for the preparation of a solid allulose material comprising crystalline allulose, the method comprising the steps of (a) providing in an evaporating crystallizer an aqueous mother liquor containing diss...
|
|
WO/2021/231751A1 |
The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection and/or to promote recovery from a respiratory pathogen infection ...
|
|
WO/2021/148618A9 |
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a...
|
|
WO/2021/208237A1 |
An application of a heptose chain-containing oligosaccharide compound in the preparation of a helicobacter pylori vaccine, relating to the field of medicines. A synthetic oligosaccharide chip is prepared by chemically synthesizing differ...
|
|
WO/2021/202883A1 |
Disclosed herein are genetically modified microorganisms and related methods for the enhanced production and export of oligosaccharides. The microorganisms described herein express major facility superfamily proteins such as CDT-1, which...
|
|
WO/2021/181349A1 |
The invention relates to a method for selective crystallization of 2'-FL from an aqueous solution comprising 2'-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.
|
|
WO/2021/183896A1 |
The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modu...
|
|
WO/2021/175878A1 |
The present invention provides a new type of galacto-oligosaccharide, having a mannose residue instead of a glucose residue at the reducing end. The invention also relates to compositions comprising this galacto-oligosaccharide, its prep...
|
|
WO/2021/172482A1 |
A method for producing a sugar anhydride, said method comprising: (1) a step for conducting a first heat treatment by heating a polysaccharide having a reducing end at 130-350°C in the presence of an alcohol compound having 1-10 carbon ...
|
|
WO/2021/163778A1 |
A biodegradable, thermoplastic, nanostructured bioresin composition is described, said composition comprising a) 10-80% by weight, in relation to the total weight of the composition, of a polymer matrix from a renewable source, comprisin...
|
|
WO/2021/160701A1 |
The invention relates to a crystalline allulose with a defined particle size distribution, to a process for the production and use thereof. The new allulose quality is characterised by the fact that it improves the shelf life of end prod...
|
|
WO/2021/160564A1 |
Proposed are allulose concentrates in solid amorphous form, which are characterised in that they contain at least approximately 20 wt. % allulose. Also proposed is a method for producing said concentrates.
|
